AGORACOM News Flash

AGORACOM Wire - Wednesday February 15th, 2012

Breaking News ....

Lomiko (LMR: TSX-V) to Complete 43-101 Report on Previous Drilling at the Quatre Milles Graphite Property *CLIENT* Read More

Top Sector Stories ....

Strike Graphite Corp. (TSXV:SRK) Acquires Wagon Graphite Project in Quebec in Vicinity of Timcal's Lac des Iles Graphite Mine *CLIENT* Read More | Profile

Strike Graphite goes "Beyond the Press Release"

McLaren Resources (CNSX:MCL) Drills 7.0 Grams Gold Over 7.4 Metres at the TimGinn Property Located Adjacent to the Hollinger Mine *CLIENT* Read More | Watch Beyond the Press Release

AGORACOM Launches GraphiteStocksBlog.com

We're proud to announce the launch of GraphiteStocksBlog.com a website dedicated to the needs of investors and companies in the fast growing Graphite industry.

INAUGURAL GRAPHITE SPONSORS

Message: If you liked the quarterly... read the annual

Reply New Message

« Prev Message Back To Forum Go to Threaded View Next Message »

sparky69

Rank: [?]

Mail Room

Points: [?]

Rating: [?]

Votes: 3 Score: 3.0

Currently 3.0/5 Stars.

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

If you liked the quarterly... read the annual

posted on Jul 02, 08 08:15AM

If you thought the quarterly was interesting, that only tells part of the story. Read the last annual.... here's an excerpt...

Let’s review the facts:

Haemacure has an extraction and purification technology that is fully developed and offers

yield enhancements of 3 to 10 times over the traditional fractionation technology,

Haemacure has a fully developed and formulated fibrin sealant that we believe performs as

well as or better than the fibrin sealants that will be on the market when it will launch its

product towards the end of 2010,

The Swiss Red Cross licensed our extraction process in the late 1990’s, scaled it up,

conducted Phase II clinical trials and built a manufacturing facility dedicated exclusively

to our fibrin sealant – this speaks to the quality of our technology,

151 patients and subjects have received our fibrin sealant in clinical trials, without any

serious adverse events related to the product being reported – this means that our fibrin

sealant is safe, therefore meeting a first key FDA metric. In addition, these earlier trials

demonstrated that the product worked very well when compared to the standard of care,

the second key FDA metric, and

Yields are 3 to 10 times higher than industry averages. We believe that Haemacure will